1. Home
  2. TOUR vs CING Comparison

TOUR vs CING Comparison

Compare TOUR & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tuniu Corporation

TOUR

Tuniu Corporation

N/A

Current Price

$5.20

Market Cap

57.6M

ML Signal

N/A

CING

Cingulate Inc.

HOLD

Current Price

$5.06

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOUR
CING
Founded
2006
2012
Country
China
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.6M
64.5M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
TOUR
CING
Price
$5.20
$5.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
7.3K
132.7K
Earning Date
06-11-2026
05-08-2026
Dividend Yield
17.12%
N/A
EPS Growth
N/A
56.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.30
N/A
Revenue Next Year
$14.00
N/A
P/E Ratio
$87.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$3.16
52 Week High
$7.79
$11.89

Technical Indicators

Market Signals
Indicator
TOUR
CING
Relative Strength Index (RSI) 59.62 49.11
Support Level $4.93 $5.08
Resistance Level $5.32 $5.20
Average True Range (ATR) 0.14 0.30
MACD 0.04 -0.04
Stochastic Oscillator 83.05 15.22

Price Performance

Historical Comparison
TOUR
CING

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: